The University of Tennessee Health Science Center

09/18/2025 | News release | Distributed by Public on 09/18/2025 13:30

2025 Avis Professorship: Howard Gendelman, MD | Reaching an Effective Immunotherapy for Alzheimer’s Disease

2025 Avis Professorship: Howard Gendelman, MD | Reaching an Effective Immunotherapy for Alzheimer's Disease

October 30, 1:00 - 2:00 pm | Pharmacy Building, Room 102

'A Presentation in the UTHSC Distinguished Lecture Series on Drug Discovery & Development'

Join the Department of Pharmaceutical Sciences for the 2025 Avis Professorship Presentation featuring this year's recipient, Howard E. Gendelman, MD., Margaret R. Larson Professor of Internal Medicine and Infectious Diseases and Chair, UNMC Department of Pharmacology and Experimental Neuroscience at College of Medicine, University of Nebraska Medical Center.

Sponsored by The Kenneth E. Avis Distinguished Visiting Professorship Endowment.

Lecture: Reaching an Effective Immunotherapy for Alzheimer's Disease

Effective therapies that target the root cause for neurodegenerative diseases have not been achieved. Combinatorial immunotherapies were developed that improve neuronal integrity and ameliorate disease signs linked to associated pathologies were achieved. They require fully characterized models for theranostic tests. Each were realized in model systems tested by noninvasive bioimaging. Confirmation were made by neuropathology, neural communication, neuroimmunity, and pharmacologic testing. Each are operative for human translation. Human cross-relevant validations were explored for how Alzheimer's disease immunotherapies can improve deficits in synaptic structures, function, neurotransmission; blood-brain barrier integrity, and neuroinflammation (both brain-infiltrating immunocytes and resident innate immune function). All were merged with studies of cognitive functions, oxidative and metabolic stress, and cellular senescence. Our newly developed humanized APP/PS1/Tau knock CRISPR mouse allowed translational studies of human immune responses during disease. The success of developmental immune-based therapeutics will be discussed.

More information can be found here.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Related

The University of Tennessee Health Science Center published this content on September 18, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 18, 2025 at 19:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]